KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Work In Process (2018 - 2020)

Historic Work In Process for Amneal Pharmaceuticals (AMRX) over the last 3 years, with Q1 2020 value amounting to $53.1 million.

  • Amneal Pharmaceuticals' Work In Process changed N/A to $53.1 million in Q1 2020 from the same period last year, while for Mar 2020 it was $53.1 million, marking a year-over-year change of. This contributed to the annual value of $58.2 million for FY2019, which is 745.31% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Work In Process stood at $53.1 million for Q1 2020.
  • In the past 5 years, Amneal Pharmaceuticals' Work In Process registered a high of $58.2 million during Q4 2019, and its lowest value of $50.8 million during Q3 2019.
  • Its 3-year average for Work In Process is $54.0 million, with a median of $53.6 million in 2018.
  • Within the past 5 years, the most significant YoY rise in Amneal Pharmaceuticals' Work In Process was 745.31% (2019), while the steepest drop was 745.31% (2019).
  • Over the past 3 years, Amneal Pharmaceuticals' Work In Process (Quarter) stood at $54.2 million in 2018, then rose by 7.45% to $58.2 million in 2019, then dropped by 8.79% to $53.1 million in 2020.
  • Its last three reported values are $53.1 million in Q1 2020, $58.2 million for Q4 2019, and $50.8 million during Q3 2019.